Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 489

Sort by

Sort Order Select

Journal Articles

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

Erika Tarasco, Lukas Bütikofer, Kenneth D. Friedman, James N. George, Ingrid Hrachovinova, Paul N. Knöbl, Masanori Matsumoto, Anne Sophie von Krogh, Isabella Aebi-Huber, Zuzana Cermakova, Magdalena Górska-Kosicka, Katarzyna A. Jalowiec, Carlo R. Largiadèr, Zoltán Prohászka, György Sinkovits, Jerzy Windyga, Bernhard Lämmle, Johanna A. Kremer Hovinga

Blood (2021) 137 (25): 3563–3575.

https://doi.org/10.1182/blood.2020009801

Published: 2021

Includes: Supplemental data

Journal Articles

Autoantibody-resistant ADAMTS13 variant

Toshiyuki Miyata

Blood (2021) 137 (19): 2575–2576.

https://doi.org/10.1182/blood.2021011147

Published: 2021

Journal Articles

N-glycan–mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP

Bogac Ercig, Nuno A. G. Graça, Kadri Kangro, Tom Arfman, Kanin Wichapong, Johana Hrdinová, Paul Kaijen, Floris P. J. van Alphen, Maartje van den Biggelaar, Karen Vanhoorelbeke, Agnès Veyradier, Paul Coppo, Chris Reutelingsperger, Gerry A. F. Nicolaes, Andres Männik, Jan Voorberg

Blood (2021) 137 (19): 2694–2698.

https://doi.org/10.1182/blood.2020007972

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

A conceptual framework for managing iTTP

Richard J. Benjamin

Blood (2021) 137 (14): 1845–1846.

https://doi.org/10.1182/blood.2021011007

Published: 2021

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

Blood (2020) 136 (3): 353–361.

https://doi.org/10.1182/blood.2019004221

Published: 2020

Includes: Supplemental data

Journal Articles

TTP: an open and shut (closed) case

Marie Scully

Blood (2020) 136 (3): 265–266.

https://doi.org/10.1182/blood.2020006444

Published: 2020

Journal Articles

HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR

Blood (2020) 135 (26): 2413–2419.

https://doi.org/10.1182/blood.2020005395

Published: 2020

Includes: Supplemental data

Journal Articles

Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy

Camila Masias, MDMPH, Krista Carter, Haiwa Wu, Shangbin Yang, PhD, Alcinda Flowers, MD, Spero Cataland, MD

Blood (2019) 134 (Supplement_1): 1098.

https://doi.org/10.1182/blood-2019-130561

Published: 2019

Journal Articles

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Javier De La Rubia, Flora Peyvandi, MD PhD, Marie Scully, Spero Cataland, MD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Paul Knoebl, MD, Ara Metjian, MD, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 1093.

https://doi.org/10.1182/blood-2019-124004

Published: 2019

Journal Articles

The Pro-Adhesive and Reduced Angiogenic Properties of Endothelial Colony Forming Cells (ECFC) from JAK2 V617F MPN Patients Are Not Related to the Expression of the JAK2 mutation in These Cells: A Potential Role of ADAM17

Bruno Kosa Lino Duarte, Stephanie Ospina-Prieto, PhD, Lucia Helena Siqueira, Jessica O F Guanaes, MSc, Fernando Ferreira Costa, MD PhD, Margareth C Ozelo, MD PhD

Blood (2019) 134 (Supplement_1): 3618.

https://doi.org/10.1182/blood-2019-131488

Published: 2019

Journal Articles

Validation of the Plasmic Score for Predicting ADAMTS13 Activity < 10% in Patients Admitted to Hospitals in Alberta with Suspected Thrombotic Thrombocytopenic Purpura

Chris Wynick, MD MSc, BSc, Joanne Britto, MD BSc, Daniel Sawler, MD BSc, Arabesque Parker, MD, Mohammad Karkhaneh, PhD, Dawn Goodyear, MD, Haowei Linda Sun, MDFRCPC

Blood (2019) 134 (Supplement_1): 2379.

https://doi.org/10.1182/blood-2019-126354

Published: 2019

Journal Articles

Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury

William E Plautz, BS, Mitchell Dyer, MD MSc, Margaret V. Ragni, MD MPH, Shannon Haldeman, Wyeth E Alexander, BS, Jason Sperry, Francis Guyette, Brian Zuckerbraun, Marian A. Rollins-Raval, MD MHP, Jay S Raval, MD, Matthew D Neal, MD

Blood (2019) 134 (Supplement_1): 444.

https://doi.org/10.1182/blood-2019-124531

Published: 2019

Journal Articles

Disruption of ADAMTS13-Autoantibody Complexes with an ADAMTS13 Spacer Domain As a Potential Therapeutic Strategy for Immune Thrombotic Thrombocytopenic Purpura

Konstantine Halkidis, MD PhD, X. Long Zheng, MD, PhD

Blood (2019) 134 (Supplement_1): 88.

https://doi.org/10.1182/blood-2019-125965

Published: 2019

Journal Articles

Adamts13-Cultured Red Blood Cells to Treat Thrombotic Thrombocytopenic Purpura

Kai Wang, PhD, Khulan Batbayar, PhD, Karl Roberts, Emmanuel Olivier, PhD, Eric E. Bouhassira, PhD

Blood (2019) 134 (Supplement_1): 89.

https://doi.org/10.1182/blood-2019-131929

Published: 2019

Journal Articles

A Case of Mistaken Identity: TTP-like State Due to Heroin Overdose

Phani Borra, MD, Cory Edward Mellon, MD

Blood (2019) 134 (Supplement_1): 4905.

https://doi.org/10.1182/blood-2019-128537

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

Plasmic and Plasic Αre Εxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes

Blood (2019) 134 (Supplement_1): 4913.

https://doi.org/10.1182/blood-2019-125343

Published: 2019

Journal Articles

ADAMTS13 Immunohistochemical Expression in Normal and Diseased Equine Tissues

Sherri Flax, MD

Blood (2019) 134 (Supplement_1): 4925.

https://doi.org/10.1182/blood-2019-127407

Published: 2019

Journal Articles

ADAMTS13, an Anti-thrombotic Protein: Evidence Outside of Thrombotic Thrombocytopenic Purpura

Simon De Meyer, PhD

Blood (2019) 134 (Supplement_1): SCI-41.

https://doi.org/10.1182/blood-2019-121114

Published: 2019

NARROW

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

Autoantibody-resistant ADAMTS13 variant

N-glycan–mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP

A conceptual framework for managing iTTP

Redefining outcomes in immune TTP: an international working group consensus report

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

TTP: an open and shut (closed) case

HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR

Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

The Pro-Adhesive and Reduced Angiogenic Properties of Endothelial Colony Forming Cells (ECFC) from JAK2 V617F MPN Patients Are Not Related to the Expression of the JAK2 mutation in These Cells: A Potential Role of ADAM17

Validation of the Plasmic Score for Predicting ADAMTS13 Activity < 10% in Patients Admitted to Hospitals in Alberta with Suspected Thrombotic Thrombocytopenic Purpura

Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury

Disruption of ADAMTS13-Autoantibody Complexes with an ADAMTS13 Spacer Domain As a Potential Therapeutic Strategy for Immune Thrombotic Thrombocytopenic Purpura

Adamts13-Cultured Red Blood Cells to Treat Thrombotic Thrombocytopenic Purpura

A Case of Mistaken Identity: TTP-like State Due to Heroin Overdose

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Plasmic and Plasic Αre Εxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes

ADAMTS13 Immunohistochemical Expression in Normal and Diseased Equine Tissues

ADAMTS13, an Anti-thrombotic Protein: Evidence Outside of Thrombotic Thrombocytopenic Purpura

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only